Survival analyses from the ZEBRA study - goserelin (Zoladex(TM)) versus CMF in premenopausal women with node-positive breast cancer

Author: Kaufmann M.   Jonat W.   Blamey R.   Cuzick J.   Namer M.   Fogelman I.   de Haes J.C.   Schumacher M.   Sauerbrei W.   on behalf of the Zoladex Early Breast Cancer Research Association ZEBRA Trialists' Group  

Publisher: Elsevier

ISSN: 0959-8049

Source: European Journal of Cancer, Vol.39, Iss.12, 2003-08, pp. : 1711-1717

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content